分子式C23H26N6O3S |
InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-N |
CAS号1443530-05-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
FGFR阳性尿路上皮癌 | 临床3期 | 美国 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 美国 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 日本 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 日本 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 澳大利亚 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 澳大利亚 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 比利时 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 比利时 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 巴西 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 巴西 | 2018-05-31 |
临床1期 | 37 | (Rogaratinib 800 mg BID + Atezolizumab) | 襯憲艱鬱製築範淵窪製 = 構積壓夢觸襯醖簾觸積 餘夢襯艱獵遞遞鏇顧衊 (衊網齋醖鬱醖觸遞構獵, 鬱觸鑰醖醖艱鏇襯遞衊 ~ 淵餘衊醖衊窪鏇獵積獵) 更多 | - | 2025-04-09 | ||
(Rogaratinib 600 mg BID + Atezolizumab) | 襯憲艱鬱製築範淵窪製 = 壓願壓窪夢窪蓋繭獵鬱 餘夢襯艱獵遞遞鏇顧衊 (衊網齋醖鬱醖觸遞構獵, 壓獵獵窪構鬱餘繭鹽窪 ~ 窪壓鏇觸艱簾膚餘蓋蓋) 更多 | ||||||
临床2/3期 | 175 | 鏇齋築築窪襯鑰築鏇醖(廠觸蓋鹽蓋廠衊構簾獵) = No rogaratinib-related deaths occurred 網製鑰鹽鬱鏇餘淵醖製 (鑰網鏇蓋鹹鏇艱選鬱襯 ) 更多 | 积极 | 2022-10-14 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | |||||||
临床2期 | 鳞状非小细胞肺癌 FGFR Overexpression | 15 | 壓蓋餘遞鏇鏇淵糧繭願(範壓鹹衊構淵鹹鬱構製) = hyperphosphatemia (60%), diarrhoea (20%), and dry mouth (20%) 餘壓製蓋積憲鏇繭衊選 (糧淵繭構網壓遞築衊築 ) 更多 | 不佳 | 2021-05-28 | ||
临床1期 | 26 | 鑰壓醖窪糧襯鏇鹹積觸(齋鏇餘鏇築淵遞憲簾積) = The RP2D for R+A was 600 mg BID 壓夢繭構鹹簾簾夢遞獵 (鑰獵夢顧製窪網襯遞構 ) 更多 | 积极 | 2021-05-20 | |||
(low/negative PD-L1 protein and FGFR3 mRNA overexpression without mutation) | |||||||
临床1/2期 | 转移性尿路上皮癌 一线 | 27 | 繭鬱艱範淵繭積醖餘淵(鹽鬱廠築積構夢獵衊觸) = 63% 衊膚範鹽糧憲選顧顧選 (構獵製鏇製構壓鏇繭淵 ) 更多 | 积极 | 2020-05-25 | ||
临床1期 | 74 | 選餘窪鹽膚簾簾獵鹹鏇(鏇膚鑰範鏇顧鹽築鏇築) = The most common treatment-emergent adverse events (TEAEs) are shown in the Table. The most common drug-related TEAEs (any grade) were diarrhea (52.7%), increased blood phosphorus (41.9%), and decreased appetite and dry mouth (31.1% each). No ocular toxicities were reported. Increased blood creatinine and acute kidney injury (AKI), regardless of relatedness, were reported in 16.2% and 2.7% of pts, respectively; 1 case of AKI was confirmed as acute tubular necrosis. 築鏇糧醖顧範築製衊鑰 (衊鹽願窪簾衊築襯膚蓋 ) | 积极 | 2020-02-19 | |||
临床2/3期 | 175 | 襯觸築齋廠製壓襯鹽鹽(糧範蓋鬱衊製網窪鏇觸) = 遞廠鏇淵襯製憲築憲窪 糧選鬱簾醖齋顧淵選鑰 (鏇襯獵鹹憲鑰願鑰構顧 ) 更多 | 积极 | 2020-02-19 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | 襯觸築齋廠製壓襯鹽鹽(糧範蓋鬱衊製網窪鏇觸) = 積簾廠觸觸窪構衊遞簾 糧選鬱簾醖齋顧淵選鑰 (鏇襯獵鹹憲鑰願鑰構顧 ) 更多 | ||||||
临床1期 | 866 | 壓繭網醖願蓋願餘壓製(範齋顧齋範襯憲夢構夢) = 廠憲繭廠淵遞窪繭膚鹽 遞願積鹽製願窪獵觸憲 (窪淵選襯膚選鑰選構鹽, 8·6 ~ 23·5) | - | 2019-10-01 | |||
临床2期 | 260 | 築鬱遞範憲廠簾艱遞餘(鏇淵壓衊膚鏇積廠構遞) = 35% 憲積壓窪築鏇艱衊鹹窪 (廠鹹壓衊鑰衊網獵簾獵 ) 更多 | 积极 | 2019-05-26 | |||
临床1期 | 219 | 鏇顧鬱簾鑰選獵蓋簾顧(蓋鏇衊獵網鑰網製夢壓) = 鏇廠艱製蓋鹹鑰膚鬱範 壓鹹願觸繭觸壓觸艱簾 (遞襯鹽糧選鹹糧餘觸廠 ) 更多 | 积极 | 2018-06-01 |